goserelin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
pituitary hormone-release stimulating peptides 1327 65807-02-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • goserelin
  • Decapeptide I
  • zoladex
  • goserelin acetate
A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.
  • Molecular weight: 1269.43
  • Formula: C59H84N18O14
  • CLOGP: -2.86
  • LIPINSKI: 3
  • HAC: 32
  • HDO: 18
  • TPSA: 493.39
  • ALOGS: -4.48
  • ROTB: 33

Drug dosage:

DoseUnitRoute
0.13 mg implant

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.04 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1989 FDA ASTRAZENECA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 702.27 20.73 300 8062 71241 53269463
Metastases to bone 601.48 20.73 190 8172 19138 53321566
Metastases to liver 482.00 20.73 165 8197 21331 53319373
Breast cancer metastatic 287.11 20.73 103 8259 15225 53325479
Neutropenia 228.49 20.73 193 8169 158992 53181712
Breast cancer 177.15 20.73 105 8257 49253 53291451
PIK3CA-activated mutation 162.31 20.73 35 8327 765 53339939
Neoplasm progression 146.30 20.73 78 8284 29841 53310863
Metastases to lymph nodes 135.47 20.73 49 8313 7391 53333313
Metastases to lung 123.90 20.73 52 8310 11652 53329052
Disease progression 114.88 20.73 108 8254 101812 53238892
Bone lesion 105.58 20.73 38 8324 5648 53335056
Metastases to skin 102.37 20.73 27 8335 1417 53339287
Abdominal lymphadenopathy 99.57 20.73 23 8339 693 53340011
Hot flush 88.29 20.73 67 8295 47093 53293611
Metastases to spine 87.04 20.73 28 8334 2962 53337742
Metastases to central nervous system 72.05 20.73 36 8326 12021 53328683
Tumour marker increased 71.81 20.73 26 8336 3927 53336777
Metastases to peritoneum 70.61 20.73 24 8338 3011 53337693
Bone disorder 63.83 20.73 40 8322 20643 53320061
Invasive lobular breast carcinoma 61.66 20.73 16 8346 787 53339917
Ascites 54.32 20.73 47 8315 39688 53301016
Drug ineffective 53.68 20.73 31 8331 817214 52523490
Osteonecrosis of jaw 51.94 20.73 44 8318 36102 53304602
Pleural neoplasm 51.83 20.73 11 8351 222 53340482
Jaundice 50.04 20.73 40 8322 30273 53310431
Osteolysis 49.40 20.73 18 8344 2767 53337937
Metastases to pleura 49.26 20.73 15 8347 1324 53339380
Lymphadenopathy 45.78 20.73 41 8321 36214 53304490
Carcinoid tumour pulmonary 45.02 20.73 11 8351 423 53340281
CYP3A4 polymorphism 42.92 20.73 8 8354 80 53340624
Breast cancer recurrent 42.37 20.73 18 8344 4147 53336557
Neuropathy peripheral 40.34 20.73 64 8298 103123 53237581
Pneumonitis 39.13 20.73 35 8327 30853 53309851
Metastases to adrenals 39.01 20.73 11 8351 742 53339962
Adnexa uteri mass 38.18 20.73 10 8352 510 53340194
Pleural effusion 37.50 20.73 57 8305 88522 53252182
Merycism 36.06 20.73 8 8354 200 53340504
Osteitis condensans 35.66 20.73 6 8356 31 53340673
Lymphadenopathy mediastinal 35.54 20.73 14 8348 2662 53338042
Osteonecrosis 35.43 20.73 31 8331 26544 53314160
Endometrial hyperplasia 34.08 20.73 10 8352 777 53339927
Breast cancer female 33.95 20.73 18 8344 6786 53333918
Fibrous histiocytoma 33.46 20.73 9 8353 509 53340195
Leukopenia 32.12 20.73 48 8314 73415 53267289
Pleural disorder 31.97 20.73 9 8353 603 53340101
Invasive ductal breast carcinoma 31.38 20.73 17 8345 6690 53334014
Amenorrhoea 31.17 20.73 19 8343 9330 53331374
Metastasis 30.86 20.73 15 8347 4716 53335988
Arachnoid cyst 29.86 20.73 7 8355 225 53340479
Dermatitis 29.15 20.73 22 8340 15304 53325400
Metastases to the mediastinum 29.01 20.73 8 8354 497 53340207
Metastases to spinal cord 28.54 20.73 5 8357 34 53340670
Palmar-plantar erythrodysaesthesia syndrome 28.39 20.73 25 8337 21581 53319123
Alanine aminotransferase increased 27.96 20.73 52 8310 95043 53245661
Uterine mass 27.30 20.73 7 8355 328 53340376
Uterine leiomyoma 27.25 20.73 17 8345 8695 53332009
Metastases to ovary 27.10 20.73 7 8355 338 53340366
Carbohydrate antigen 15-3 increased 26.04 20.73 9 8353 1187 53339517
Hepatic cancer 25.58 20.73 12 8350 3489 53337215
Uterine polyp 25.48 20.73 10 8352 1883 53338821
Cervical polyp 24.86 20.73 6 8356 219 53340485
Musculoskeletal chest pain 24.29 20.73 22 8340 19700 53321004
Hepatic lesion 23.40 20.73 12 8350 4225 53336479
Central nervous system lesion 22.52 20.73 16 8346 10146 53330558
Mood swings 22.51 20.73 20 8342 17466 53323238
Bile duct stenosis 22.40 20.73 8 8354 1161 53339543
Aspartate aminotransferase increased 22.30 20.73 44 8318 83985 53256719
Bone pain 21.96 20.73 33 8329 50689 53290015
Depressed mood 21.94 20.73 28 8334 36936 53303768
Metastases to pelvis 21.91 20.73 6 8356 363 53340341
Metastases to nervous system 21.84 20.73 4 8358 36 53340668
Ocular icterus 21.47 20.73 11 8351 3868 53336836
Lymphangioleiomyomatosis 20.97 20.73 5 8357 173 53340531
Gamma-glutamyltransferase increased 20.84 20.73 26 8336 33529 53307175

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis of jaw 286.59 16.21 130 9268 19036 32485092
Prostatic specific antigen increased 214.76 16.21 95 9303 13092 32491036
Metastases to bone 183.57 16.21 80 9318 10630 32493498
Prostate cancer metastatic 127.68 16.21 52 9346 5833 32498295
Malignant neoplasm progression 127.33 16.21 134 9264 78362 32425766
Prostate cancer 124.95 16.21 85 9313 27321 32476807
Interstitial lung disease 110.81 16.21 114 9284 64887 32439241
Osteonecrosis 98.99 16.21 61 9337 16561 32487567
Hot flush 92.11 16.21 57 9341 15589 32488539
Osteomyelitis 60.74 16.21 44 9354 15589 32488539
Tooth extraction 48.21 16.21 25 9373 4877 32499251
Death 45.41 16.21 224 9174 382293 32121835
Pain in jaw 41.17 16.21 32 9366 12594 32491534
Osteitis 40.97 16.21 16 9382 1605 32502523
Haematuria 40.05 16.21 59 9339 48302 32455826
Blood testosterone increased 39.71 16.21 14 9384 1055 32503073
Bone pain 38.84 16.21 38 9360 20306 32483822
Bone disorder 37.79 16.21 24 9374 6856 32497272
Pituitary haemorrhage 36.63 16.21 9 9389 188 32503940
Pituitary tumour benign 35.08 16.21 12 9386 826 32503302
Contracted bladder 33.66 16.21 6 9392 22 32504106
Eosinophilic cystitis 33.25 16.21 6 9392 24 32504104
Exposed bone in jaw 32.20 16.21 14 9384 1843 32502285
Hepatic function abnormal 31.90 16.21 51 9347 44789 32459339
Hypocalcaemia 31.44 16.21 36 9362 23018 32481110
Cancer pain 26.98 16.21 14 9384 2732 32501396
PO2 increased 26.15 16.21 9 9389 631 32503497
Metastases to spine 25.84 16.21 13 9385 2380 32501748
Device expulsion 25.21 16.21 6 9392 109 32504019
Bone sequestrum 25.03 16.21 9 9389 718 32503410
Gingivitis 24.65 16.21 14 9384 3266 32500862
Injection site haemorrhage 24.35 16.21 20 9378 8508 32495620
Gingival erythema 23.67 16.21 6 9392 143 32503985
Purulent discharge 23.17 16.21 13 9385 2963 32501165
Ubiquinone decreased 23.06 16.21 4 9394 12 32504116
Arterial injury 22.36 16.21 7 9391 364 32503764
PCO2 decreased 21.70 16.21 10 9388 1510 32502618
Injection site haematoma 21.52 16.21 10 9388 1538 32502590
Blood alkaline phosphatase increased 20.76 16.21 35 9363 32097 32472031
Central nervous system mass 20.70 16.21 5 9393 97 32504031
Bone lesion 20.62 16.21 12 9386 2931 32501197
Urinary retention 20.61 16.21 37 9361 35660 32468468
Wall motion score index abnormal 20.37 16.21 5 9393 104 32504024
Haemoglobin decreased 20.12 16.21 78 9320 119593 32384535
Bone debridement 19.26 16.21 6 9392 307 32503821
Protein total decreased 18.92 16.21 14 9384 5116 32499012
Atopy 18.85 16.21 5 9393 143 32503985
Sequestrectomy 18.45 16.21 6 9392 353 32503775
Airway remodelling 18.28 16.21 5 9393 161 32503967
Toxicity to various agents 18.04 16.21 15 9383 178026 32326102
Pulmonary embolism 17.87 16.21 59 9339 83600 32420528
Gingival swelling 16.91 16.21 8 9390 1281 32502847
Drug ineffective 16.77 16.21 56 9342 383421 32120707

Pharmacologic Action:

SourceCodeDescription
ATC L02AE03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONES AND RELATED AGENTS
Gonadotropin releasing hormone analogues
FDA MoA N0000175654 Gonadotropin Releasing Hormone Receptor Agonists
FDA EPC N0000175655 Gonadotropin Releasing Hormone Receptor Agonist
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018931 Antineoplastic Agents, Hormonal

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Endometriosis indication 129103003
Hormone receptor positive malignant neoplasm of breast indication 417181009
Advanced Prostatic Carcinoma indication
Endometrial Ablation Adjunct indication
Urinary tract obstruction contraindication 7163005 DOID:5200
Hypercholesterolemia contraindication 13644009
Hypertensive disorder contraindication 38341003 DOID:10763
Hypercalcemia contraindication 66931009 DOID:12678
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Pregnancy, function contraindication 289908002
Bilateral orchidectomy contraindication 386634006
Cardiovascular event risk contraindication 395112001
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
Smokes tobacco daily contraindication 449868002
Bone Metastases contraindication
Vertebral Metastases contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.85 acidic
pKa2 9.65 acidic
pKa3 11.9 acidic
pKa4 12.55 acidic
pKa5 13.03 acidic
pKa6 13.27 acidic
pKa7 13.43 acidic
pKa8 10.75 Basic
pKa9 6.69 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Gonadotropin-releasing hormone receptor GPCR AGONIST CHEMBL CHEMBL
Lutropin-choriogonadotropic hormone receptor GPCR WOMBAT-PK

External reference:

IDSource
N0000007256 NUI
D00573 KEGG_DRUG
145781-92-6 SECONDARY_CAS_RN
4019508 VANDF
C0120107 UMLSCUI
CHEBI:5523 CHEBI
CHEMBL1201247 ChEMBL_ID
CHEMBL1200501 ChEMBL_ID
D017273 MESH_DESCRIPTOR_UI
DB00014 DRUGBANK_ID
3879 IUPHAR_LIGAND_ID
5943 INN_ID
0F65R8P09N UNII
5311128 PUBCHEM_CID
203146 RXNORM
1550 MMSL
4799 MMSL
d01354 MMSL
003532 NDDF
006407 NDDF
008308 NDDF
008309 NDDF
108771008 SNOMEDCT_US
108773006 SNOMEDCT_US
126138002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZOLADEX HUMAN PRESCRIPTION DRUG LABEL 1 50090-3466 IMPLANT 3.60 mg SUBCUTANEOUS NDA 26 sections
ZOLADEX HUMAN PRESCRIPTION DRUG LABEL 1 70720-950 IMPLANT 3.60 mg SUBCUTANEOUS NDA 26 sections
ZOLADEX HUMAN PRESCRIPTION DRUG LABEL 1 70720-951 IMPLANT 10.80 mg SUBCUTANEOUS NDA 26 sections